Abivax (CHIX:ABVXP) Other Operating Expense : €-4.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Other Operating Expense?

Abivax's Other Operating Expense for the six months ended in Dec. 2023 was €-2.34 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.62 Mil.

Abivax's quarterly Other Operating Expense increased from Dec. 2022 (€-37.25 Mil) to Jun. 2023 (€-2.28 Mil) but then declined from Jun. 2023 (€-2.28 Mil) to Dec. 2023 (€-2.34 Mil).

Abivax's annual Other Operating Expense increased from Dec. 2021 (€-57.48 Mil) to Dec. 2022 (€-55.35 Mil) and increased from Dec. 2022 (€-55.35 Mil) to Dec. 2023 (€-4.62 Mil).

Abivax Other Operating Expense Historical Data

The historical data trend for Abivax's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Other Operating Expense Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

0.21

-1.37

-57.48

-55.35

-4.62

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Operating Expense	Get a 7-Day Free Trial															-0.29	-18.10	-37.25	-2.28	-2.34

Abivax Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.62 Mil.

Abivax Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Abivax's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax (CHIX:ABVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (CHIX:ABVXp) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X10:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.

Abivax (CHIX:ABVXP) Headlines

No Headlines